AstraZeneca to buy Gracell Technologies for $1.2bn

by | Dec 27, 2023

(Sharecast News) – AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.
Under the terms of the deal, AstraZeneca will acquire all of Gracell’s shares at $2 per share in cash, plus a non-tradable contingent value right of $0.30 per ordinary share payable upon achievement of a specified regulatory milestone.

The upfront cash portion represents a 62% premium to Gracell’s closing market price on December 22, 2023.

Reporting by Frank Prenesti for Sharecast.com

Related articles

Swisscom weighing offer for Vodafone’s Italian business

Swisscom weighing offer for Vodafone’s Italian business

(Sharecast News) - Swiss telecommunications firm Swisscom has been mulling over an offer for Vodafone's Italian operations early next year, according to Bloomberg, potentially countering a rival bid from Iliad SA. The potential deal will see Vodafone's mobile service...

SSP expands into Canada, Saudi Arabia

SSP expands into Canada, Saudi Arabia

(Sharecast News) - International travel food and beverage outlet operator SSP Group on Thursday said it had expanded into Canada and Saudi Arabia as it pivots to high-growth markets. The company, which owns the Upper Crust and Ritazza brands, said it had bought...

Redde Northgate approaches Halfords over £1.4bn tie up – report

Redde Northgate approaches Halfords over £1.4bn tie up – report

(Sharecast News) - Van rental outfit Redde Northgate has made a £1.4bn merger approach for high street bike and car repair chain Halfords, the Sunday Telehgraph reported, citing unnamed sources. The report stated the duo held detailed talks about a possible tie-up...

Trending stories

Join our mailing list

Subscribe to our mailing list to receive regular updates!

x